top

  Info

  • Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.

  Info

  • Utilizzare questo link per rimuovere la selezione effettuata.

Biblioteca

MARC Lista (tabellare)
Acne : current concepts and management / / Dae Hun Suh, editor
Acne : current concepts and management / / Dae Hun Suh, editor
Pubbl/distr/stampa Cham, Switzerland : , : Springer, , [2021]
Descrizione fisica 1 online resource (194 pages)
Disciplina 616.53
Collana Updates in clinical dermatology
Soggetto topico Acne - Treatment
Acne
Terapèutica
Soggetto genere / forma Llibres electrònics
ISBN 3-030-68996-4
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Intro -- Preface -- Contents -- Contributors -- 1: Update on Cutibacterium acnes -- Introduction -- Cutibacterium acnes (Ex - Propionibacterium acnes) Identity Passport -- Bacteriological Description -- Ecological Niches -- Taxonomy Modification -- Phylogeny -- Growth Culture Conditions -- Virulence Factors -- Resistance in Acne Context -- Acne in the Genomic Era -- Cutibacterium acnes and Cutaneous Microbiome Interactions -- Cutibacterium acnes and Innate Immunity -- What Alternatives in the Future? -- Microbiome and Probiotics Approach -- Phage Therapy Approach -- Vaccine Approach -- Conclusion -- References -- 2: Updates in Isotretinoin -- Introduction -- Dosing -- Laboratory Monitoring -- Depression -- Procedures -- Conclusion -- References -- 3: Developing a Core Outcome Set for Acne Clinical Trials: Towards Standardization and Harmonization -- Why Perform Interventional Clinical Trials? -- Measurement Issues in Clinical Trials -- Issue with Acne Clinical Trials -- Regulatory Guidance -- Need for Standardization -- What Are Core Outcome Sets? -- Core Outcome Sets in Dermatology -- Process of Determining Acne Core Domains -- Summary -- References -- 4: Adult Acne Vulgaris -- Epidemiology and Characteristics of Adult Acne -- Pathogenesis of Adult Acne -- Genetics -- Dysbiosis -- Insulin-Like Growth Factor 1 -- Diagnostic Considerations and Patient Evaluation in Adult Acne -- Acne Distribution and Severity Grading in Adult Acne -- Severe Adult Acne and Associated Syndromes -- Autoinflammatory Syndromes -- Disorders of Endocrine Metabolism -- Dietary Factors in Adult Acne -- Approach to Evaluation of Adults with Acne -- Therapeutic Options for Adult Acne -- Topical Dapsone -- Oral Anti-androgens -- Combined Oral Contraceptive Pills -- Oral Spironolactone -- Oral Metformin -- Laser and Light Therapies for Adult Acne.
Treatment of Adult Acne During Pregnancy and Lactation -- Comparison of Guidelines on Adult Acne -- Prognosis and Long-Term Outcomes -- Conclusion -- References -- 5: Topical Retinoids and Acne -- Introduction -- Structure and Mechanism of Action -- All-Trans Retinol and All-Trans Retinoic Acid -- Adapalene -- Tazarotene -- Trifarotene -- Combination Therapies -- Adverse Effects -- Topical Retinoids in the Treatment of Acne Sequelae -- References -- 6: New Drug Developments in Acne -- Introduction -- Limitations of Acne Treatment -- Methodology -- New Drug Developments in Acne -- Topical Drugs -- Effects on Sebum Production -- Effects on Follicular Hyperkeratosis -- Effects on the Microbiota -- Systemic Acne Drugs Under Investigation in Phase 1 and 2 Trials -- Effects on Sebum Production -- Effects on the Microbiota -- Biologics with Different Actions in Acne -- Further Agents with Anti-inflammatory Effects -- Other Systemic Compounds Under Investigation -- Summary -- References -- 7: Scientific Connection Between Acne and Diet -- References -- 8: Photodynamic Therapy for Acne Vulgaris: Mechanism and Clinical Practice -- Mechanism of PDT in Acne -- PDT on Sebaceous Glands -- Antimicrobial Effects -- Anti-inflammation Effects -- Clinical Practice of PDT in Acne -- Photosensitizer -- Light Source -- Incubation Time -- Skin Preparation -- Adverse Effects -- Conclusion -- References -- 9: Insulin Resistance Associated Acne -- Molecular Aspects of IRAA -- Racial, Ethnic, Regional, Geographic Aspects of IRAA -- Clinical Profile of IRAA -- Companion Morphologies in IRAA -- IRAA Comorbidities -- Pathogenesis of IRAA -- Laboratory Validation of IRAA -- Treatment of IRAA -- References -- 10: Acne Fulminans -- Introduction -- Epidemiology -- Pathogenesis -- Associated Disorders -- Classification -- Clinical Presentation -- Histology -- Laboratory Findings.
Imaging -- Differential Diagnosis -- Treatment -- Systemic Treatment -- Miscellaneous -- Topical Treatment -- Physical Treatment -- References -- 11: Acne and Environmental Factors -- Introduction -- Chloracne -- Cigarette Smoking and Acne -- Coal Tar Acne -- UV and Acne -- Conclusions -- References -- 12: Acne on Pigmented Skin -- References -- 13: Up-to-Date Therapeutic Approaches for Acne Scars in a Korean Dermatology Clinic -- Introduction -- Treatment Modalities -- Overview of Fractional Laser Technology -- Non-ablative Fractional Laser (NAFL) -- Ablative Fractional Laser (AFL) -- Picosecond Lasers with a Diffractive Optic Element (P-DOE) -- Fractional Microneedling Radiofrequency (FMR) -- Chemical Peeling -- Mini-surgical Techniques -- Transcutaneous Pneumatic Injection of Solutions -- Fillers -- Autologous Fibroblast Transplantation -- Biologic Materials -- Treatments for Hypertrophic Scars and Keloidal Acne Scars -- Practical Perspectives for "Real-World" Treatments: Author's Opinion -- Multimodal Approaches for Individual Atrophic Scar Subtypes -- Common Procedures -- Ice Pick Scars -- Rolling Scars -- Boxcar Scars -- Hypertrophic and Keloidal Scars -- Acne Scar Related to Dyschromia -- Concurrent Treatments with Active Acne -- Conclusion -- References -- 14: Innate and Adaptive Immunity in Acne Vulgaris -- Introduction -- Immune Events Are Crucial in All Stages of Acne Pathogenesis -- Discovery of the Immune Properties of Keratinocytes -- Innate Immune Events -- The Role of Keratinocytes in Acne Pathogenesis -- Sebocytes Are Active Players in Acne Immunity Too -- Adaptive Immune Regulation in Acne -- Not All C. acnes Strains Are Created to Be Equal? -- Acne Has a Complex Pathogenesis -- Literature -- 15: Clinical Features and Differential Diagnosis of Acne Vulgaris -- The Purpose of This Chapter -- Clinical Features of Acne Vulgaris.
Special Forms of Acne -- Neonatal Acne, Acne Neonatorum (Fig. 15.1) -- Acne Conglobata -- Acne Fulminans -- Cosmetic Acne Including Pomade Acne -- Acne Excoriee (Fig. 15.2) -- Steroid Acne -- Chloracne Including Dioxin Acne -- Other Drug-Induced Acnes -- Hormonal Acne (Fig. 15.3) -- SAPHO, PAPA, PASH, and PAPASH Syndromes -- Clinical Differential Diagnosis of Acne -- Rosacea (Fig. 15.4) -- Perioral Dermatitis (Fig. 15.5) -- Folliculitis -- Malassezia Folliculitis (Fig. 15.6) -- Demodicosis (Fig. 15.7) -- Folliculitis Barbae -- Pseudofolliculitis Barbae -- Eosinophilic Pustular Folliculitis (Ofuji Disease) -- Acneiform Eruption Due to Anti-EGFR Drugs or Other Anticancer Drugs (Figs. 15.8 and 15.9) -- Lupus Miliaris Disseminatus Faciei -- Milium -- Angiofibroma (Tuberous Sclerosis) (Fig. 15.10) -- Syringomas -- Flat Warts (Fig. 15.11) -- Others -- Conclusion -- References -- 16: Epidemiology of Acne in Latin America and Research News from Brazil -- Acne Vulgaris -- Inflammation -- Classification -- Prevalence and Clinical Forms -- Quality of Life -- Algorithm of Treatment -- Oral Isotretinoin -- Controversies About Oral Isotretinoin -- Brazilian Similar Product -- Adult Female Acne -- Epidemiology in Latin America -- Quality of Life -- Inflammation: Molecular Mechanism -- Hormonal Metabolism -- Practical Guide for Management -- References -- 17: Androgens and Acne -- Introduction -- Androgen-Related Pathophysiology of AV -- Androgens and Altered Sebum Production and Composition -- Androgens in Epidermal Dyskeratinization in Hair Follicles -- Androgens in Cutaneous Inflammation -- Androgen-Related Clinical Implications -- Anabolic-Androgenic Steroid-Induced Acne in Bodybuilders -- Androgen-Induced Acne in Transgender Men -- Acne in Androgen-Mediated Conditions (Polycystic Ovarian Syndrome, PCOS) -- Antiandrogenic Treatments in AV -- Conclusion.
References -- Index.
Record Nr. UNINA-9910495214103321
Cham, Switzerland : , : Springer, , [2021]
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Advances in Cancer Treatment [[electronic resource] ] : From Systemic Chemotherapy to Targeted Therapy / / by Iago Dillion Lima Cavalcanti, José Cleberson Santos Soares
Advances in Cancer Treatment [[electronic resource] ] : From Systemic Chemotherapy to Targeted Therapy / / by Iago Dillion Lima Cavalcanti, José Cleberson Santos Soares
Autore Cavalcanti Iago Dillion Lima
Edizione [1st ed. 2021.]
Pubbl/distr/stampa Cham : , : Springer International Publishing : , : Imprint : Springer, , 2021
Descrizione fisica 1 online resource (VIII, 109 p. 27 illus., 25 illus. in color.)
Disciplina 616.994
Soggetto topico Oncology
Internal medicine
Pharmacy
Cancer—Treatment
Tumor markers
Cancer
Nanomedicine
Internal Medicine
Cancer Therapy
Tumour Biomarkers
Cancer Nanotechnology
Oncologia
Terapèutica
Fisiologia patològica
Nanomedicina
Soggetto genere / forma Llibres electrònics
ISBN 3-030-68334-6
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Introduction -- Cancer: concepts and epidemiology -- A brief history of cancer -- What is Cancer? -- Cancer Epidemiology -- Cancer development and immunology -- Cell cycle -- Cell cycle control: the function of cyclins -- Cancer triggering agents -- Proto-oncogenes -- Tumor suppressor genes -- Development of tumor mass -- Cancer Immunology -- Discovery of tumor markers -- Cancer diagnosis -- Impact of the discovery of tumor markers -- Main tumor markers for cancer diagnosis -- Alpha-fetoprotein (AFP) -- Human Chorionic Gonadotropin (β-HCG) -- Mucin-like cancer-associated antigen (MCA) -- CA 15.3 -- Carcinoembryonic antigen (CEA) -- Bladder tumor antigen (BTA) -- Telomerase -- Nuclear matrix protein (NMP 22) -- Cyfra 21.1 -- Prostatic acid phosphatase (PAP) -- Prostate-specific antigen (PSA) -- CA 125 -- CA 19.9 -- p53 -- CA 72.4 -- K-ras -- HER2 -- Cancer staging -- Conventional cancer treatment -- Therapeutic modalities of cancer -- Surgery -- Radiotherapy -- Antineoplastic chemotherapy -- Classification of antineoplastic agents by cycle -- Specific cycle antineoplastics -- Nonspecific antineoplastic agents -- Classification of antineoplastic agents by chemical structure and function -- Alkylating agents -- Antimetabolites -- Plant-derived antineoplastics -- Antitumor antibiotics -- Chemotherapy toxicity -- Hematological toxicity -- Liver toxicity -- Cardiac toxicity -- Anthracyclines -- Fluoropyrimidine -- Taxanes -- Pulmonary toxicity -- Neurological toxicity -- Renal toxicity -- Gastrointestinal toxicity -- Metabolic changes -- Targeted therapies in cancer treatment -- Overexpressed receptors on tumor cells -- Immunotherapy -- Monoclonal antibodies -- Types of monoclonal antibodies -- Side effects of monoclonal antibodies -- Checkpoint Inhibitors -- Side effects of checkpoint inhibitors -- Cancer Vaccines -- Vaccines in cancer prevention -- Vaccines for the treatment of cancer -- Non-specific immunotherapies -- Tyrosine kinase inhibitors -- Imatinib -- Gefitinib -- Erlotinib -- Sorafenib -- Dasatinib -- Nilotinib -- Lapatinib -- Adverse events of tyrosine kinase inhibitors -- Conventional chemotherapy vs. targeted therapy -- Differences between conventional chemotherapy and targeted therapy -- Risks and benefits of conventional chemotherapy compared to targeted therapy -- Eligibility criteria for the indication of the targeted therapy -- Side effects of targeted therapy -- Can targeted therapy replace conventional chemotherapy? -- Targeted therapy associated with conventional chemotherapy -- Pharmaceutical nanotechnology applied to cancer -- Pharmaceutical nanotechnology -- Classification of nanosystems -- Liposomes -- Micelles -- Polymeric nanoparticles -- Solid lipid nanoparticles -- Magnetic nanoparticles -- Metal nanoparticles -- Main functions of nanosystems in cancer -- Pharmaceutical nanotechnology in cancer diagnosis -- Pharmaceutical nanotechnology for cancer treatment.
Record Nr. UNINA-9910484989203321
Cavalcanti Iago Dillion Lima  
Cham : , : Springer International Publishing : , : Imprint : Springer, , 2021
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Advances in the Diagnosis and Treatment of Sleep Apnea [[electronic resource] ] : Filling the Gap Between Physicians and Engineers / / edited by Thomas Penzel, Roberto Hornero
Advances in the Diagnosis and Treatment of Sleep Apnea [[electronic resource] ] : Filling the Gap Between Physicians and Engineers / / edited by Thomas Penzel, Roberto Hornero
Edizione [1st ed. 2022.]
Pubbl/distr/stampa Cham : , : Springer International Publishing : , : Imprint : Springer, , 2022
Descrizione fisica 1 online resource (386 pages)
Disciplina 170
Collana Advances in Experimental Medicine and Biology
Soggetto topico Biotechnology
Neurology
Biomedical engineering
Biomedical Engineering and Bioengineering
Apnea
Terapèutica
Soggetto genere / forma Llibres electrònics
ISBN 3-031-06413-5
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Section A Physiology -- An Overview On Sleep Medicine -- Covering The Gap Between Sleep And Cognition – Mechanisms and Clinical Examples -- Obstructive sleep apnoea: Focus on Pathophysiology -- Diagnosis of obstructive sleep apnea in patients with associated comorbidity -- Pediatric Obstructive Sleep Apnea: What’s in a Name? -- Treatment of Cheyne-Stokes respiration in heart failure with adaptive servo-ventilation: An integrative model -- Section B Diagnostic innovations -- Automated scoring of sleep and associated events -- Conventional machine-learning methods applied to the automatic diagnosis of sleep apnea -- Home Sleep Testing of Sleep Apnea -- ECG and heart rate variability in sleep-related breathing disorders -- Cardiopulmonary Coupling -- Pulse oximetry: the working principle, signal formation, and applications -- Oximetry indices in the management of sleep apnea: from overnight minimum saturation to the novel hypoxemia measures -- Airflow Analysis In The Context OF Sleep Apnea -- Deep-learning Model Based on Convolutional Neural Networks to Classify Apnea-hypopnea Events From The Oximetry Signal -- Tracheal sound analysis -- Obstructive Sleep Apnea with COVID-19 -- Section C Therapeutic innovations -- APAP, BPAP, CPAP and new modes of positive airway pressure therapy -- Adherence monitoring using telemonitoring techniques -- Innovations in The Treatment of Pediatric Obstructive Sleep Apnea -- Hypoglossal Nerve Stimulation Therapy -- Anna M. Mohammadieh -- Index.
Record Nr. UNINA-9910616388403321
Cham : , : Springer International Publishing : , : Imprint : Springer, , 2022
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Asthma : pathophysiology, herbal and modern therapeutic interventions / / Sheikh Rayees, Inshah Din
Asthma : pathophysiology, herbal and modern therapeutic interventions / / Sheikh Rayees, Inshah Din
Autore Rayees Sheikh
Pubbl/distr/stampa Cham, Switzerland : , : Springer, , [2021]
Descrizione fisica 1 online resource (ix, 69 pages) : illustrations
Disciplina 616.23807
Collana SpringerBriefs in Immunology
Soggetto topico Asthma - Pathophysiology
Asma
Fisiologia patològica
Terapèutica
Farmàcia homeopàtica
Soggetto genere / forma Llibres electrònics
ISBN 3-030-70270-7
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Intro -- Introduction -- Contents -- Chapter 1: Asthma -- Chapter 2: Types of Asthma -- 2.1 Mild to Moderate Asthma -- 2.2 Severe Asthma -- 2.3 Pathophysiology Asthma -- 2.4 Interleukin-5 -- 2.5 Interleukin-13 -- 2.6 Interleukin-4 -- Chapter 3: Airway Inflammation and Airway Hyperresponsiveness -- Chapter 4: Effects of Inflammation -- 4.1 Effects on Airway Epithelia -- 4.2 Fibrosis -- 4.3 Mucus Hypersecretion -- 4.4 Airway Smooth Muscle -- Chapter 5: Inflammatory Cells Involved in Asthma -- 5.1 Eosinophils -- 5.2 Mast Cells -- 5.3 Macrophages -- 5.4 Dendritic Cells -- 5.5 CD4+T Cells -- 5.5.1 Activation and Differentiation -- 5.5.2 Th2 Cells and Asthma -- Chapter 6: Transcription Factors Involved in Th2 Cell Differentiation -- Chapter 7: Current Asthma Treatments -- 7.1 Inhaled Corticosteroids -- 7.2 Adverse Effects -- 7.3 Leukotriene Antagonists -- 7.4 Adverse Effects -- 7.5 Short-Acting Beta2 Agonists -- 7.6 Adverse Effects -- 7.7 Long-Acting Beta2 Agonists -- 7.8 Adverse Effects -- 7.9 Phosphodiesterase Inhibitors and Methylxanthines -- 7.10 Adverse Effects -- 7.11 Anticholinergics (Anti-muscarinic) -- 7.12 Adverse Effects -- Chapter 8: Cytokine-Based Therapies -- 8.1 Anti-IL-9 Therapy -- 8.2 Anti-IL-13 Therapy -- 8.3 Anti-IL-4 Therapy -- 8.4 Anti-IL-17 Therapy -- 8.5 Anti-IgE Therapy -- 8.6 Anti-IL-5 Therapy -- 8.7 Anti-TSLP -- Chapter 9: Transcription Factor Modulators -- 9.1 STAT6 -- 9.2 GATA3 -- 9.3 NF-κB and AP-1 -- Chapter 10: Preclinical Mouse Models of Asthma Used to Evaluate Drug Efficacy and Properties and Associated Drawbacks -- Chapter 11: Herbal Treatments of Asthma -- Chapter 12: Traditional Plants with Anti-asthmatic Potential -- Chapter 13: Asthma Chinese Herbal Remedies -- 13.1 Anti-asthma Herbal Medicine Intervention (ASHMI) -- 13.2 Modified Mai Men Dong Tang (mMMDT) -- 13.3 Ding Chuan Tang -- 13.4 STA-1.
13.5 Sophora flavescens Ait -- 13.6 Ma Huang -- 13.7 Minor Blue Dragon -- 13.8 Ginkgo biloba -- 13.9 Ginseng -- 13.10 Liquorice -- 13.11 Zizyphi fructus and Zizyphus jujuba -- 13.12 Cinnamon -- 13.13 Blipleuru -- 13.14 Sckisandra Ckintvisis -- 13.15 Ligusticum wallichii -- 13.16 Other Herbs -- Chapter 14: Future Potential of Herbal-Based Medicinal Treatment for Management of Asthma -- References.
Record Nr. UNINA-9910484355303321
Rayees Sheikh  
Cham, Switzerland : , : Springer, , [2021]
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Behavioral sleep medicine : a practical guide for adult and pediatric providers / / Lisa Medalie ; with contributions by David Gozal and Kathryn Hansen ; foreword by Hrayr Attarian
Behavioral sleep medicine : a practical guide for adult and pediatric providers / / Lisa Medalie ; with contributions by David Gozal and Kathryn Hansen ; foreword by Hrayr Attarian
Autore Medalie Lisa
Pubbl/distr/stampa Cham, Switzerland : , : Springer, , [2022]
Descrizione fisica 1 online resource (128 pages)
Disciplina 616.89142
Soggetto topico Behavior therapy
Sleep disorders
Sleep disorders in children
Trastorns del son
Terapèutica
Teràpia de la conducta
Soggetto genere / forma Llibres electrònics
ISBN 3-031-12574-6
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Intro -- Foreword -- Introduction -- Acknowledgments -- Contents -- 1: Cognitive Behavioral Treatment for Insomnia -- 1.1 Visit 1: Intake and Sleep Hygiene -- 1.1.1 Provider Intake Form -- 1.1.2 Intake Script -- 1.1.3 Sleep Hygiene Clinic Talking Points -- 1.1.4 Sleep Hygiene Patient Handout -- 1.1.5 Chronic Insomnia Diagnostic Criteria -- Chronic Insomnia Disorder -- 1.1.6 Short-Term Insomnia Diagnostic Criteria -- Short-Term Insomnia Disorder -- Alternate Names -- 1.1.7 Other Insomnia Disorder Diagnostic Criteria -- Other Insomnia Disorder -- 1.1.8 Cognitive Behavioral Treatment for Insomnia Sleep Log -- 1.1.9 Weekly Questionnaire for Cognitive Behavioral Treatment for Insomnia Sessions -- 1.1.10 Sleep Hygiene Reading List -- 1.2 Visit 1 Add-on (As Needed): Sleep Medication Taper -- 1.2.1 Medication Taper Clinic Talking Points -- 1.2.2 Sleep Medication Taper Patient Handout -- 1.2.3 Sleep Medication Taper Reading List -- 1.3 Visit 2: Stimulus Control and Sleep Restriction -- 1.3.1 Behavioral Sleep Medicine Follow-up Form -- 1.3.2 Stimulus Control Clinic Talking Points -- 1.3.3 Stimulus Control Patient Handout -- 1.3.4 Stimulus Control Reading List -- 1.3.5 Sleep Restriction Clinic Talking Points -- 1.3.6 Sleep Restriction Patient Handout -- 1.3.7 Sleep Restriction Reading List -- 1.4 Visit 3: Relaxation Strategies -- 1.4.1 Relaxation Strategies Clinic Talking Points -- 1.4.2 Relaxation Strategies Patient Handout -- 1.4.3 Relaxation Strategies Reading List -- 1.5 Visit 4: Worry-time -- 1.5.1 Worry-time Clinic Talking Points -- 1.5.2 Worry-time Patient Handout -- 1.5.3 Worry-time Reading List -- 1.6 Visit 5: Identifying Cognitive Errors -- 1.6.1 Identifying Cognitive Errors Clinic Talking Points -- 1.6.2 Identifying Cognitive Errors Patient Handouts -- 1.6.3 Common Cognitive Errors.
1.6.4 Identifying Cognitive Errors Questionnaire -- 1.7 Visit 6: Cognitive Restructuring -- 1.7.1 Cognitive Restructuring Clinic Talking Points -- 1.7.2 Cognitive Restructuring Patient Handout -- 1.7.3 Cognitive Restructuring Reading List -- 1.8 Visit 7: Maintenance and Relapse Prevention -- 1.8.1 Maintenance and Relapse Prevention Clinic Talking Points -- 1.8.2 Maintenance and Relapse Prevention Patient Handout -- Bibliography -- 2: Pediatric Behavioral Sleep Medicine -- 2.1 Visit 1: Intake and Sleep Hygiene -- 2.1.1 Provider Intake Form -- 2.1.2 Pediatric Sleep Hygiene Clinic Talking Points -- 2.1.3 Pediatric Sleep Hygiene Handout -- 2.1.4 Pediatric Sleep Log for Parents -- 2.1.5 Brief Sleep Screen for Pediatrics -- 2.1.6 Provider Notes Regarding Pediatric Treatment Plans -- 2.2 Pediatric Follow-up: Learning Independent Sleep -- 2.2.1 Standard and Graduated Extinction Clinic Talking Points -- 2.2.2 Standard Extinction Parent Handout -- 2.2.3 Graduated Extinction Parent Handouts -- 2.2.4 Standard and Graduated Extinction Reading List -- 2.2.5 Bedtime Pass Clinic Talking Points -- 2.2.6 Bedtime Pass Parent Handout -- 2.2.7 Bedtime Pass Reading List -- 2.2.8 Evening Schedule Clinic Talking Points -- 2.2.9 Evening Schedule Parent Handout -- 2.2.10 Evening Schedule/Bedtime Routine Reading List -- 2.2.11 Behavior Chart Clinic Talking Points -- 2.2.12 Behavior Chart Clinic Parent Handout -- 2.2.13 Behavior Chart Reading List -- Bibliography -- 3: Actigraphy -- 3.1 Actigraphy Clinic Talking Points -- 3.2 Actogram Example -- 3.2.1 Actogram -- 3.3 Actigraphy Reading List -- 4: CBT for CPAP Adherence -- 4.1 Visit 1: Intake and Treatment Planning -- 4.1.1 Initial Visit Clinic Talking Points -- 4.2 CPAP Intake Form -- 4.2.1 CPAP Adherence Barriers Guide -- 4.2.2 Obstructive Sleep Apnea, Adult Diagnostic Criteria.
Obstructive Sleep Apnea, Adult -- 4.2.3 Obstructive Sleep Apnea, Pediatric Diagnostic Criteria -- Obstructive Sleep Apnea, Pediatric -- 4.3 CPAP Adherence Patient Handouts -- 4.3.1 Psychoeducation Patient Handout -- 4.4 CPAP Adherence Patient Handouts -- 4.4.1 Desensitization Patient Handout -- 4.5 CPAP Adherence Patient Handouts -- 4.5.1 Motivational Enhancement Patient Handout -- 4.6 CPAP Adherence Patient Handouts -- 4.6.1 Adherence Tracking -- 4.6.2 CPAP Adherence Reading List -- Bibliography -- 5: Imagery Rehearsal Therapy for Nightmare Disorder -- 5.1 Visit 1: Nightmare Intake and Psychoeducation -- 5.1.1 IRT Introduction Clinic Talking Points -- 5.1.2 Provider Guide to Comorbidities and Differentials -- 5.1.3 Imagery Rehearsal Therapy Intake Form -- 5.1.4 Nightmare Disorder Diagnostic Criteria -- Nightmare Disorder -- 5.1.5 Nightmare Psychoeducation Patient Handout -- 5.1.6 Imagery Rehearsal Therapy Tracking Form -- 5.1.7 Imagery Rehearsal Therapy Reading List -- 5.2 Visit 2: Positive Imagery -- 5.2.1 Positive Imagery Clinic Talking Points -- 5.2.2 Positive Imagery Reading List -- 5.3 Visit 3: Rescripting -- 5.3.1 Rescripting Clinic Talking Points -- 5.3.2 Rescripting Reading List -- 5.4 Visit 4: Rescripting Follow-up -- 5.4.1 Rescripting Follow-up Clinic Talking Points -- 5.5 Visit 5: Maintenance and Relapse Prevention -- 5.5.1 Maintenance and Relapse Prevention Clinic Talking Points -- Bibliography -- 6: Delayed Sleep Phase Syndrome -- 6.1 Provider Guide to Assessment -- 6.2 Delayed Sleep-Wake Phase Disorder Diagnostic Criteria -- 6.2.1 Delayed Sleep-Wake Phase Disorder -- 6.3 Circadian Rhythm Screening Tool -- 6.4 Delayed Sleep Phase Syndrome Clinic Talking Points -- 6.5 Delayed Sleep Phase Syndrome Sleep Hygiene Handout -- 6.6 Delayed Sleep Phase Syndrome Tracking.
6.7 Delayed Sleep Phase Syndrome Patient Handout -- 6.8 Delayed Sleep Phase Syndrome Reading List -- Bibliography -- 7: Night Eating Syndrome -- 7.1 Night Eating Syndrome Clinic Talking Points -- 7.2 Proposed Diagnostic Criteria for Night Eating Syndrome -- 7.3 Night Eating Questionnaire -- 7.4 Night Eating Syndrome Tracking -- 7.5 Night Eating Syndrome Patient Handout -- 7.6 Night Eating Syndrome Reading List -- Bibliography -- 8: Parasomnias -- 8.1 Parasomnias Clinic Talking Points -- 8.1.1 Psychoeducation -- 8.1.2 Triggers -- 8.1.3 Sleepwalking -- 8.1.4 Sleep Terrors -- 8.1.5 Sleep Enuresis -- 8.2 Sleepwalking Diagnostic Criteria -- 8.2.1 Sleepwalking -- 8.2.2 Alternate Names -- 8.2.3 Sleep Terrors Diagnostic Criteria -- Sleep Terrors -- Alternate Names -- 8.2.4 Sleep Enuresis Diagnostic Criteria -- Sleep Enuresis -- 8.2.5 Parasomnias Sleep Need Handout -- 8.2.6 Parasomnias Log -- 8.2.7 Parasomnias Reading List -- Bibliography -- 9: Society for Behavioral Sleep Medicine (SBSM) Resources -- 9.1 SBSM Resource List Link -- 9.2 Theories -- 9.2.1 Classic and Operant Conditioning -- 9.2.2 Shaping/Exposure -- 9.2.3 Reinforcement Schedules, Extinction, Spontaneous Recovery -- 9.2.4 Placebo Effect -- 9.2.5 Theories of Behavioral Change -- 9.2.6 Relaxation -- 9.2.7 Acceptance & -- Commitment Therapy / Mindfulness -- 9.2.8 Cognitive Restructuring -- 9.2.9 Behavioral Activation -- 9.3 Physiology -- 10: Behavioral Sleep Medicine Board Preparation -- 10.1 Becoming Certified -- 10.1.1 Requirements for Certification -- Eligibility Requirements for Examination -- 10.1.2 Frequently Asked Questions from the SBSM -- Who Is Eligible to Apply for DBSM Certification? -- What Disciplines Are Included as Eligible to Obtain a BSM Certification? -- Once I Obtain BSM Certification, Will I Need to Renew it?.
Do I Need to Take the BSM Exam to Obtain a DBSM if I Am Already Credentialed in Sleep Medicine or Sleep Dentistry? -- Who Can I Contact to Get my Questions Answered About the BSM Exam? -- Index.
Record Nr. UNINA-9910637733403321
Medalie Lisa  
Cham, Switzerland : , : Springer, , [2022]
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Biology and treatment of leukemia and bone marrow neoplasms / / Vinod Pullarkat, Guido Marcucci, editors
Biology and treatment of leukemia and bone marrow neoplasms / / Vinod Pullarkat, Guido Marcucci, editors
Pubbl/distr/stampa Cham, Switzerland : , : Springer, , [2021]
Descrizione fisica 1 online resource (200 pages)
Disciplina 616.99
Collana Cancer treatment and research
Soggetto topico Acute leukemia
Leukemia
Leukemia, Myeloid, Acute
Myelodysplastic Syndromes
Bone Marrow Neoplasms
Leucèmia mieloide
Terapèutica
Soggetto genere / forma Llibres electrònics
ISBN 3-030-78311-1
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Record Nr. UNINA-9910502610603321
Cham, Switzerland : , : Springer, , [2021]
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Bipolar disorder : from neuroscience to treatment / / Allan H. Young, Mario F. Juruena, editors
Bipolar disorder : from neuroscience to treatment / / Allan H. Young, Mario F. Juruena, editors
Pubbl/distr/stampa Cham, Switzerland : , : Springer, , [2021]
Descrizione fisica 1 online resource (viii, 325 pages)
Disciplina 616.89506
Collana Current Topics in Behavioral Neurosciences
Soggetto topico Bipolar disorder - Treatment
Trastorn bipolar
Terapèutica
Soggetto genere / forma Llibres electrònics
ISBN 3-030-72143-4
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Intro -- Preface -- Contents -- The Neurobiology of Bipolar Disorder -- 1 Introduction -- 2 Neurotransmitters -- 2.1 Serotoninergic System -- 2.2 Dopaminergic System -- 2.3 Norepinephrinergic System -- 2.4 GABAergic System -- 2.5 Glutamatergic System -- 3 Intracellular Signalling -- 4 Adenylate Cyclase Signalling Pathway -- 5 Neurotrophins and Neurogenesis -- 6 Neuroendocrine -- 7 Conclusion -- References -- The Role of Stress in Bipolar Disorder -- 1 Introduction -- 1.1 Activation of Hormonal Systems After Stress -- 1.2 Stress Hormone Receptors -- 2 Stress Hormone Actions on the Brain in Healthy Individuals -- 2.1 Cellular Effects of Stress Hormones on Brain Circuits -- 2.2 Neuronal Circuits and Cognitive Function -- 3 Changes in Stress Responsiveness in Bipolar Disorder -- 3.1 Imbalance in the Stress System: Importance of Genetic and (Early) Life History -- 3.2 Changes in the HPA Axis in Bipolar Disorder Patients -- 4 Changes in Cognitive Function in Bipolar Disorder Related to Stress -- 4.1 Time-Dependent Changes in Cognitive Processing Following Stress in BD Patients -- 4.2 Network Function in BP Patients and Individuals at Risk for Psychopathology -- 5 Concluding Remarks -- References -- The Role of Genetics in Bipolar Disorder -- 1 Introduction: Why Genetics Matters in the Susceptibility to Bipolar Disorder? -- 2 Bipolar Disorder Is Heritable: Twin, Adoption, and Family Studies -- 3 How Many Genes Modulate the Risk of Bipolar Disorder? Linkage Studies, Candidate Gene Studies, and Genome-Wide Association S... -- 4 Genetic Overlap Between Bipolar Disorder and Other Brain Disorders: Disorder-Specific or General Genetic Influences? -- 5 The Role of Rare Genetic Variants -- 6 Gene x Environment Studies -- 7 Nongenetic Mechanisms Contributing to the Regulation of Gene Expression: Epigenetics -- 8 Current and Future Lines of Research.
9 Conclusion -- References -- Targeting Mitochondrial Dysfunction for Bipolar Disorder -- 1 The Mitochondria -- 1.1 Mitochondria as an Energy Source -- 1.2 Other Functions of Mitochondria -- 2 Reactive Oxygen Species and Oxidative Stress -- 3 Mitochondria in Bipolar Disorder -- 3.1 Possible Mechanisms of Mitochondrial Dysfunction in Bipolar Disorder -- 3.1.1 A Shift from OXPHOS to Glycolysis -- 3.1.2 Creatine Kinase -- 3.1.3 Calcium -- 3.1.4 Increased Oxidative Stress -- 3.1.5 Neurotransmitters -- 3.1.6 Brain-Derived Neurotrophic Factor (BDNF) -- 3.1.7 NAA -- 3.1.8 Bcl-2 -- 3.2 Mitochondrial Genes -- 4 How Conventional Drugs for Bipolar Disorder Relate to Mitochondrial Functioning -- 5 Mitochondrial Potential Treatments -- 5.1 Likely Beneficial -- 5.1.1 PPAR Agonists -- 5.1.2 Minocycline -- 5.1.3 N-Acetyl-Cysteine (NAC) -- 5.1.4 Co-enzyme Q10 -- 5.1.5 Melatonin -- 5.2 Theoretically Beneficial, but No Studies Have Been Published -- 5.2.1 Ebselen -- 5.2.2 Mangosteen -- 5.2.3 Ketogenic Diet -- 5.2.4 Resveratrol -- 5.2.5 Taurine -- 5.3 Unlikely to Be Beneficial -- 5.3.1 Alpha-Lipoic Acid (ALA) -- 5.3.2 Pyrimidines -- 5.4 Potential Risk of a Manic Switch -- 5.4.1 ALC (Acetyl-L-Carnitine) -- 5.4.2 Creatine Monohydrate (CM) -- 5.4.3 SAMe (S-Adenosyl-Methionine) -- 5.5 Vitamins -- 5.5.1 Vitamin A -- 5.5.2 Vitamin C -- 5.5.3 Vitamin D -- 5.5.4 Vitamin E -- 5.5.5 Vitamins B -- 6 Summary -- References -- Intracellular Signaling Cascades in Bipolar Disorder -- 1 Introduction -- 2 Mitochondrial Dysfunction -- 3 Calcium Channel Modulators -- 4 Intracellular Signaling and Inflammation -- 5 Glycogen Synthase Kinase 3-Beta (GSK3β) -- 6 Protein Kinase C (PKC) and Diacylglycerol (DAG) -- 7 Neurotrophins -- 8 Glutamatergic System -- 9 Dopaminergic System -- 10 Neurohormonal System -- 11 Purinergic System and Mania -- 12 Conclusion -- References.
Sleep and Circadian Rhythm Disorder in Bipolar Affective Disorder -- 1 Bipolar Affective Disorder -- 2 Circadian Rhythm -- 3 Circadian Rhythm and Bipolar Affective Disorder -- 4 Circadian Rhythm Sleep-Wake Disorders -- 4.1 Delayed Sleep Phase Disorder -- 5 Genetics -- 6 Chronotype -- 7 Melatonin and Cortisol -- 8 Social Zeitgeber Theory -- 9 Circadian Rhythm and Bipolar Disorder -- 10 Conclusion -- References -- Neuroendocrine Stress System in Bipolar Disorder -- 1 Introduction -- 2 Endocrine Axis -- 2.1 Regulation of the Hypothalamic-Pituitary-Adrenal Axis -- 2.2 The Glucocorticoid Receptor (GR) -- 2.3 Mineralocorticoid Receptors (MRs) -- 2.4 Molecular Mechanisms for Resistance of Glucocorticoid Receptors -- 3 Abnormalities of the HPA Axis in Depression -- 3.1 Impact of Stress on Bipolar Disorders -- 3.2 Impact of Mediating Factors on the HPA Axis -- 4 Factors Associated with an Endophenotype Increasing Vulnerability -- 5 Conclusion -- References -- Neuroanatomic and Functional Neuroimaging Findings -- 1 Introduction -- 2 Structural Neuroimaging and Diffusion Tensor Imaging Studies -- 2.1 Structural Magnetic Resonance Imaging MRI (sMRI) Findings in BD -- 2.2 Diffusion Tensor Imaging (DTI) Findings in BD -- 2.3 Longitudinal sMRI and DTI Findings -- 3 Functional Neuroimaging -- 3.1 Positron Emission Tomography (PET) -- 3.2 Resting-State Functional MRI (rsfMRI) -- 4 Summary of Main Findings -- 5 Diagnostic Specificity of Neuroimaging Findings -- 5.1 Structural Neuroimaging and DTI Findings -- 5.2 Functional Neuroimaging Findings (PET, rs-fMRI) -- 5.3 Neuroimaging and Pattern Classification Methods and the Diagnosis of BD -- 6 Perspectives on the Role of Neuroimaging in the Management of BD Patients -- 6.1 Neuroimaging Studies and Bipolar Disorders Mood States -- 6.2 Neuroimaging Studies, Bipolar Disorders, and Pharmacological Treatment.
6.3 Neuroimaging to Predict Pharmacological Treatment Response -- 6.4 Neuroimaging and Psychotherapy in Bipolar Disorders -- 7 Conclusions -- References -- Structural and Functional Brain Correlates of Neuroprogression in Bipolar Disorder -- 1 Introduction -- 2 Structural Aspects of Neuroprogression in Neuroimaging -- 2.1 Evidence from Cross-Sectional Studies -- 2.1.1 Brain Volume and General Findings -- 2.1.2 Prefrontal Cerebral Cortex -- 2.1.3 Cingulate Cortex -- 2.1.4 Temporal-Limbic Structures -- 2.1.5 Other Brain Structures -- 2.2 Evidence from Longitudinal Studies -- 2.2.1 Brain Volume and General Findings -- 2.2.2 Prefrontal Cerebral Cortex -- 2.2.3 Cingulate Cortex -- 2.2.4 Temporal-Limbic Structures -- 3 Functional Aspects of Neuroprogression in Neuroimaging -- 4 Challenges (Limitations) and Perspectives -- References -- Inflammation as a Mechanism of Bipolar Disorder Neuroprogression -- 1 Introduction -- 2 Evidence of Inflammatory and Infectious Diseases in BD Neuroprogression -- 2.1 Maternal Immune Activation as a Risk Factor for BD Development and Neuroprogression -- 2.2 Role of Infectious Disease as a Trigger to Develop BD Neuroprogression -- 2.3 Autoimmune Disorders and Their Association with BD Neuroprogression -- 2.4 Role of the Gut-Brain Axis on BD Neuroprogression -- 3 Inflammatory and Oxidative Mechanisms in BD Neuroprogression -- 3.1 Mechanisms of Inflammation and Their Contribution to BD Neuroprogression -- 3.2 Oxidative Stress and Mitochondrial Dysfunction Associated with BD Neuroprogression -- 3.3 Peripheral Inflammatory Mediators as a Trigger or Accelerator of BD Neuroprogression -- 3.4 Cerebrospinal Fluid (CSF) System Inflammatory Markers in BD Neuroprogression -- 3.5 Postmortem Inflammatory Markers in BD Neuroprogression -- 4 Conclusions and Future Directions -- References -- Neuropsychology of Bipolar Disorder.
1 Pattern and Magnitude of Impairment -- 2 What Are the Factors that Affect Cognition? -- 2.1 Diagnostic Features -- 2.2 Sleep -- 2.3 Physical Health -- 2.4 Medication -- 3 Summary -- 4 Methods of Assessment -- 4.1 Longitudinal Changes -- 4.2 Identifying Neuropsychological Phenotypic Clusters -- 4.3 Hierarchical Organization of Cognition -- 4.4 Experimental Analysis Methods -- 5 Conclusions -- References -- The Kindling/Sensitization Model and Early Life Stress -- 1 Introduction -- 2 Stress Sensitization -- 3 Stimulant-Induced Behavioral Sensitization -- 4 Episode-Induced Sensitization -- 5 Cross-Sensitization: Neurochemical Commonalities and Inflammatory Mechanisms -- 6 An Epigenetic Basis for Sensitization -- 7 One Genetic and Two Epigenetic Bases for Illness Vulnerability -- 8 More Stress, Episodes, and Substance Abuse in the USA Than Europe Driving Sensitization -- 9 Implications for Treatment -- 10 High Risk Children Deserve Special Attention and Treatment -- 11 Measures Considered for Primary and Secondary Prevention -- 12 Conclusions -- References -- Childhood Maltreatment in Bipolar Disorders -- 1 Introduction -- 2 Childhood Maltreatment and (More Severe) Bipolar Disorders -- 2.1 Childhood Maltreatment as a Risk Factor for Developing Bipolar Disorders -- 2.2 Childhood Maltreatment and the Severity of the Clinical Expression of Bipolar Disorders -- 2.3 Childhood Maltreatment, Psychiatric, and Medical Comorbidities in Bipolar Disorders -- 2.4 Issues About Childhood Maltreatment Subtypes, the Timing of Exposure, and Gender -- 3 Moving to Dimensions of Psychopathology in Association with Childhood Maltreatment -- 3.1 Childhood Maltreatment and Dimensions of Psychopathology in Bipolar Disorders -- 3.2 Childhood Maltreatment and Cognition in Bipolar Disorders -- 4 Childhood Maltreatment as Part of a Multiple Hit Model of Susceptibility.
4.1 Interactions Between Childhood Maltreatment and the Genetic Susceptibility to Bipolar Disorders.
Record Nr. UNINA-9910485147503321
Cham, Switzerland : , : Springer, , [2021]
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Breast cancer, from bench to personalized medicine / / edited by Saima Shakil Malik and Nosheen Masood
Breast cancer, from bench to personalized medicine / / edited by Saima Shakil Malik and Nosheen Masood
Pubbl/distr/stampa Gateway East, Singapore : , : Springer, , [2022]
Descrizione fisica 1 online resource (534 pages)
Disciplina 616.9449
Soggetto topico Breast - Cancer - Treatment
Breast - Cancer
Càncer de mama
Terapèutica
Soggetto genere / forma Llibres electrònics
ISBN 981-19-0197-X
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Intro -- Foreword -- Preface -- Acknowledgment -- Contents -- About the Editors -- Part I: Overview of Breast Cancer -- 1: Epidemiology and Risk Factors of Breast Cancer -- 1.1 Introduction -- 1.1.1 Invasive Ductal Carcinoma -- 1.1.2 Invasive Lobular Carcinoma -- 1.2 Morphological and Molecular Classification of Breast Tumors -- 1.2.1 Morphological Classification -- 1.2.2 Molecular Classification -- 1.3 Global Distribution and Epidemiology of Breast Cancer -- 1.4 Risk Factors Influencing Tumor Behavior -- 1.4.1 Genetic Factors -- 1.4.1.1 BRCA -- 1.4.1.2 PALB2 -- 1.4.1.3 TP53 -- 1.4.1.4 ATM -- 1.4.1.5 CDH1 -- 1.4.1.6 CHEK2 -- 1.4.1.7 STK11 -- 1.4.1.8 NF1 -- 1.4.1.9 NBN -- 1.4.2 Epigenetic Factors -- 1.4.3 Demographic Factors -- 1.4.4 Blood Group -- 1.4.5 Reproductive Factors -- 1.4.5.1 Menarche Age -- 1.4.5.2 Full-Term Pregnancy -- 1.4.5.3 Abortion -- 1.4.5.4 Menstrual Cycle -- 1.4.6 Endocrine Factors -- 1.4.6.1 Contraceptive Methods -- 1.4.6.2 Ovulation-Stimulating Drugs -- 1.4.6.3 Postmenopausal Hormone Therapy -- 1.4.7 Family History -- 1.4.8 Breast Density and Lactation -- 1.4.9 Environmental Factors -- 1.4.9.1 Environmental Factors -- 1.4.9.2 Radiation -- 1.4.9.3 Exposure to Various Chemicals -- 1.4.9.4 Lifestyle Factors -- 1.4.9.5 Body Mass Index (BMI) -- 1.4.9.6 Hyperglycemia -- 1.4.9.7 Alcohol Consumption -- 1.4.9.8 Smoking -- 1.4.9.9 Diet -- 1.4.9.10 Sleep Patterns -- 1.4.9.11 Caffeine -- 1.4.9.12 Physical Activity -- 1.4.9.13 Vitamin D -- 1.4.9.14 Socioeconomic Status -- 1.5 Prevention Strategies and Treatments for Breast Cancer -- 1.6 Conclusion -- References -- 2: Histopathological Characteristics: Breast Cancer Subtypes Depending on Receptor Status, Clinical and Pathological Staging o... -- 2.1 Introduction -- 2.2 Histological Classification of Breast Cancer -- 2.2.1 Invasive Breast Cancer -- 2.2.1.1 Invasive Ductal Carcinoma.
2.2.1.1.1 Medullary Breast Carcinoma -- Histological Organization of Medullary Breast Carcinoma -- 2.2.1.1.2 Metaplastic Carcinoma -- Histological Organization of Metaplastic Breast Cancer -- 2.2.1.1.3 Adenoid Cystic Carcinoma -- Histological Organization of Adenoid Cystic Carcinoma of Breast -- 2.2.1.1.4 Mucinous Carcinoma -- Histological Organization of Mucinous Carcinoma -- 2.2.1.1.5 Tubular Carcinoma -- Histological Organization of Tubular Carcinoma -- 2.2.1.1.6 Carcinoma with Papillary Morphology -- Histological Organization of Papillary Carcinoma -- 2.2.1.1.7 Apocrine Carcinoma (Androgen-Receptor Positive and Estrogen-Receptor Negative) -- Histological Organization of Apocrine Carcinoma -- 2.2.1.1.8 Neuroendocrine Carcinoma -- Histological Organization of Neuroendocrine Carcinoma -- 2.2.1.2 Invasive Lobular Carcinoma -- 2.2.1.2.1 Histological Organization of Invasive Lobular Carcinoma. -- 2.3 Conclusion -- References -- 3: Relationship of Breast Cancer with Other Hormone-Sensitive Cancers -- 3.1 Introduction -- 3.2 Role of Hormones in Breast Cancer -- 3.2.1 Tumor-Promoting Effects of Estrogen -- 3.2.2 Tumor-Promoting Effects of Progesterone -- 3.2.3 Melatonin and Hormone-Dependent Breast Cancer -- 3.2.4 Hormonal Contraception and Breast Cancer -- 3.2.5 Menopause Hormone Therapy and Breast Cancer -- 3.3 Relation Between Breast Cancer and Other Hormones Related to Cancer -- 3.3.1 Different Hormones Sensitive Cancers -- 3.3.2 Breast Cancer and Ovarian Cancer -- 3.3.3 Breast Cancer and Endometrial Cancer -- 3.4 Biomarkers in Breast and OHRC -- 3.4.1 N1-Acetylspermidine as a Chemical Biomarker -- 3.4.2 Mucin-1, Urokinase-Type Plasminogen Activator as Protein Biomarker -- 3.4.3 Ki-67 as a Prophetic Marker in Breast Cancer -- 3.4.4 HER2 as a Prophetic Marker in Breast Cancer -- 3.5 Genetics Behind Hormonal Breast Cancer.
3.5.1 BRCA1 and BRCA2 Gene Mutation -- 3.5.2 High Menace Gene Mutations in PALB2, PTEN, and TP53 Genes -- 3.5.3 Moderate Menace Gene Mutations in ATM and cdh1genes -- 3.5.4 Less Risk Gene Mutations in CHEK2, NBN, NF1, and STK11 Genes -- 3.6 Conclusion -- References -- 4: Cancer Care and Psychosocial Needs -- 4.1 Introduction -- 4.1.1 Death and Survival Rates -- 4.1.2 Risk Factors -- 4.1.2.1 Inherent Risk Factors -- 4.1.2.2 Environmental Factors -- 4.1.2.3 Behavioral Risk Factors -- 4.2 Living with Cancer -- 4.2.1 Adjusting to Diagnosis and Treatment -- 4.3 Cancer Induced Stressor -- 4.3.1 Psychosocial Stressors -- 4.3.2 Consequences of Stressors -- 4.4 Psychosocial Aspects of Cancer -- 4.4.1 Social Support -- 4.4.2 Communication -- 4.4.3 Management of Psychosocial Aspects -- 4.4.4 Psychotherapy with Cancer Patients -- References -- Part II: Cell and Molecular Biology of Breast Cancer (Diagnosis and Prognosis) -- 5: Implications of BRCA1, BRCA2 Gene in Overall Development and Prognosis of Breast Cancer -- 5.1 Introduction -- 5.1.1 Genes Related to Breast Cancer -- 5.2 Importance of Detection of BRCA Mutations -- 5.3 Pathology of BRCA1 and BRCA2 Associated Breast Cancers -- 5.3.1 BRCA-1 and BRCA-2 Probability Models -- 5.3.2 BOADICEA Model -- 5.3.3 BRCAPRO Model -- 5.3.4 Couch Model -- 5.3.5 Manchester Model -- 5.3.6 Myriad Model -- 5.3.7 Tyrer-Cuzick Model -- 5.4 Implication of BRCA1/2 in Hereditarily Onset of Breast Cancer -- 5.5 Advantages and Disadvantages of Screening and Genetic Testing -- 5.5.1 Advantages of Screening and Genetic Testing -- 5.5.2 Disadvantages of Screening and Genetic Testing -- 5.6 Future Perspective -- References -- 6: Early-Stage Progression of Breast Cancer -- 6.1 Early-Stage Progression of Breast Cancer -- 6.2 Epigenetics in Breast Cancer Progression -- 6.3 Molecular Classification of Breast Cancer.
6.4 ERPT Positive Group: Luminal Type -- 6.5 ERNT Negative Group -- 6.5.1 HER2 Enriched Subclass -- 6.5.2 Breast Like -- 6.5.3 Basal Like -- 6.6 Progression of Breast Cancer and Role of Cell Specific Polarity Proteins -- 6.7 Role of High and Low Penetrance Genes -- 6.8 High Penetrance Breast Cancer Genes -- 6.9 BRCA1 and BRCA2 -- 6.9.1 PALB2 -- 6.9.2 TP53 -- 6.9.3 PTEN -- 6.9.4 STK11 -- 6.9.5 CDH1 -- 6.10 Low Penetrance Breast Cancer Genes -- References -- 7: Noninvasive Biomarkers: Emerging Trends in Early Detection of Breast Cancer -- 7.1 Introduction -- 7.2 Types of Noninvasive Biomarkers -- 7.2.1 Blood-Based Biomarker -- 7.2.1.1 Circulating Carcinoma Proteins -- 7.2.1.2 Circulating Tumor Cells -- 7.2.1.3 Circulating Cell-Free Tumor DNA -- 7.2.1.4 Circulating miRNAs -- 7.2.1.5 Extracellular Vesicles -- 7.2.1.6 Other Blood-Based Biomarkers -- 7.2.2 Non-blood-Based Biomarkers -- 7.2.2.1 Tears -- 7.2.2.2 Breath -- 7.2.2.3 Nipple Aspirate Fluid -- 7.2.2.4 Apocrine Sweat -- 7.2.2.5 Urine -- 7.3 Biomarkers Involved in Cancer Progression/Proliferation -- 7.3.1 circRNAs -- 7.3.2 miRNAs -- 7.4 Biomarkers Involved in Cancer Metastasis -- 7.4.1 miRNAs -- 7.4.2 Chemokines -- 7.5 Biomarkers Involved in Cancer Drug Resistance -- 7.5.1 circRNA -- 7.5.2 miRNA -- 7.6 Progress of Breast Cancer Biomarker Research: Limitations, Challenges, and Future Perspective -- 7.7 Conclusion -- References -- 8: Epigenetics Involvement in Breast Cancer -- 8.1 Introduction -- 8.2 Epigenetics and Breast Cancer -- 8.3 Epigenetic Mechanisms in the Breast Cancer -- 8.3.1 DNA Methylation -- 8.3.2 Histone Modifications -- 8.3.3 Non-coding RNAs (ncRNAs) -- 8.4 Epigenetics as a Diagnostic Tool for Breast Cancer -- 8.4.1 DNA Methylation as Potential Diagnostic Biomarker -- 8.4.2 Non-coding RNAs as Potential Diagnostic Biomarker -- 8.5 Epigenetics as Predictive Biomarkers.
8.5.1 DNA Methylation as Predictive Markers -- 8.5.2 Histone Modifications as Predictive Biomarkers -- 8.5.3 ncRNAs as Potential Predictive Biomarkers -- 8.6 Epigenetics as Prognostic Markers in Breast Cancer -- 8.6.1 DNA Methylation as a Prognostic Biomarker -- 8.6.2 Histone Modification as a Biomarker -- 8.6.3 Non-coding RNAs as Prognostic Biomarkers -- 8.7 Epigenetics Modifications as Therapeutic Target -- 8.8 Conclusion -- References -- 9: Role of Fibrinolytic Mechanisms in Breast Cancer Diagnosis, Prognosis, and Treatment -- 9.1 Introduction: Fibrinolysis and Fibrinolytic System -- 9.2 Breast Cancer Etiology -- 9.3 Pathologies Associated with Fibrinolytic System in Breast Cancer -- 9.3.1 Breast Cancer Progression and Role of Hemostatic Function -- 9.4 Components of Fibrinolytic System -- 9.4.1 Plasminogen and Plasmin -- 9.4.2 Thrombin -- 9.4.3 Tissue Factors -- 9.5 Fibrinolytic System as Diagnostic Target -- 9.5.1 Prognostic Biomarkers -- 9.5.2 Diagnostic Biomarkers -- 9.6 Fibrinolytic System as Therapeutic Target -- 9.6.1 Inhibitors of Coagulation -- 9.6.2 Transcriptional Repression -- 9.6.3 Small Molecules and Epigenetic Agents -- 9.6.4 Toxin Conjugates -- 9.6.5 Antibodies -- 9.6.6 Peptide Inhibitors -- 9.6.7 Natural and Chemical Products -- 9.6.8 Aptamers -- 9.7 Conclusion and Future Directions -- References -- 10: MicroRNAs and Noncoding RNAs as Gene Regulators and Potential Therapeutic Agents -- 10.1 Introduction -- 10.2 Biogenesis of miRNA -- 10.2.1 Canonical Pathway Aimed at miRNA Biogenesis -- 10.2.2 Non-canonical Pathway Aimed at miRNA Biogenesis -- 10.3 MicroRNAs as a Gene Regulator -- 10.3.1 MicroRNAs Mediated Gene Silencing -- 10.3.2 MicroRNA-Mediated Translational Activation -- 10.4 Significance of Noncoding RNA into the Breast Cancer -- 10.4.1 miRNA and Breast Cancer -- 10.4.1.1 miRNAs Serve as a Tumor Suppressor.
10.4.1.1.1 Let-7 Family.
Record Nr. UNINA-9910568287503321
Gateway East, Singapore : , : Springer, , [2022]
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Burn and trauma associated lung injury / / Zhao-Fan Xia, Feng Zhu, Yu Sun (editors)
Burn and trauma associated lung injury / / Zhao-Fan Xia, Feng Zhu, Yu Sun (editors)
Edizione [1st ed. 2020.]
Pubbl/distr/stampa Gateway East, Singapore : , : Springer, , [2020]
Descrizione fisica 1 online resource (XX, 169 p. 22 illus., 14 illus. in color.)
Disciplina 611.24
Soggetto topico Lungs - Wounds and injuries - Treatment
Pulmó
Traumatisme
Ferides i lesions
Terapèutica
Soggetto genere / forma Llibres electrònics
ISBN 981-15-7056-6
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Inhalation injury -- Primary Blast Lung injury -- Pulmonary barotrauma -- Delayed Hemopneumothorax -- Sepsis Related Lung Injury (SRLI) -- Ventilator-Associated Lung Injury (VALI) -- Ischemia-reperfusion and Oxidative Stress Induced Lung Injury -- Pulmonary Enbolism -- Pulmonary Infection -- Modes and Strategies of Mechanical Ventilation for burn and trauma associated lung injury -- Potential Therapy.
Record Nr. UNINA-9910440646403321
Gateway East, Singapore : , : Springer, , [2020]
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Burning mouth disease : a guide to diagnosis and management / / Isaäc van der Waal
Burning mouth disease : a guide to diagnosis and management / / Isaäc van der Waal
Autore Waal Isaäc van der <1943->
Pubbl/distr/stampa Cham, Switzerland : , : Springer, , [2021]
Descrizione fisica 1 online resource (167 pages)
Disciplina 616.31
Soggetto topico Mouth - Diseases - Diagnosis
Mouth - Diseases - Treatment
Malalties de la boca
Diagnòstic
Terapèutica
Soggetto genere / forma Llibres electrònics
ISBN 3-030-71640-6
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Record Nr. UNINA-9910484526603321
Waal Isaäc van der <1943->  
Cham, Switzerland : , : Springer, , [2021]
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui